Canaccord Genuity Maintains Hold on Sage Therapeutics, Lowers Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Sumant Kulkarni maintains a Hold rating on Sage Therapeutics (NASDAQ:SAGE) and lowers the price target from $21 to $17.
April 26, 2024 | 12:56 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Canaccord Genuity maintains a Hold rating on Sage Therapeutics and lowers the price target from $21 to $17.
The reduction in price target by Canaccord Genuity suggests a bearish outlook on the stock's short-term price movement, potentially leading to a negative impact on investor sentiment and the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100